Good alternative for patients with renal dysfunction unable to safely use dabigatran (I'd be much more comfortable using this drug in patients with moderate renal impairment, regardless of what the PI for dabigatran says). Much more user-friendly than enoxaparin, so that's a plus.
As a poster mentioned above, I don't think the book is closed on hepatic dysfunction. It's an oxazolidinone derivative, just like linezolid, so I think there are going to be rare mytochondrial toxicities, including neuropathy, hepatic dysfunction and bone marrow suppression. The pre-marketing studies and in vitro data say that rivaroxaban doesn't have binding affinity for mitochondrial DNA, but I'm not convinced - especially when it starts being used off-label on a long-term basis.